ClinicalTrials.gg
Active, not recruitingNCT04751578AAA-SHAPE_NLDUpdated Dec 22, 2025

Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - Netherlands

An interventional study of IMPEDE-FX Embolization Plug in Abdominal Aortic Aneurysm, sponsored by Shape Memory Medical, Inc.. Active, not recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Shape Memory Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Aortic Aneurysm, Abdominal with a site in Netherlands — 14 open to participants now, 22 under way, none of them phase 3. Aortic Aneurysm, Abdominal · Netherlands.

Enrollment
19th of 22
15 · median 67
Started
2021
with 2 others
No phase
18 of 62
6 open now
Primary completion
2022-04
later than 1 of 21 live
Registered
44th of 62
by date

Among the 62 studies in Aortic Aneurysm, Abdominal with a site in Netherlands, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2021, is one of 18 with no phase, reaches primary completion later than 1 of the 21 other live ones, and was the 44th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

14 of the 62 studies in Aortic Aneurysm, Abdominal with a site in Netherlands are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Aortic Aneurysm, Abdominal with a site in Netherlands, or all of them as a file.
02

Study summary

To determine the safety and efficacy of IMPEDE-FX Embolization Plug and/or IMPEDE-FX Rapid Fill to fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft.

03

Conditions studied

  • Abdominal Aortic Aneurysm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • A candidate for elective EVAR of an infrarenal aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women

Exclusion criteria

Exclusion Criteria:

  • An inability to provide
  • Enrolled in another clinical study
  • Aortoiliac aneurysm, or concomitant iliac artery ectasia or aneurysm (common iliac artery diameter >24 mm) close to the bifurcation and/or that cannot be adequately sealed
  • Patent AAA sac feeding vessels (within the sac) >4 mm in diameter
  • Volume of AAA sac to be filled after stent graft placement \<20 mL or >135 mL, based on pre-procedure CTA (i.e. aortic flow volume exclusive of stent graft volume)
  • Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, or Medtronic Endurant II Stent Graft to treat the AAA
  • Planned use of the chosen stent graft outside its instructions for use (IFU)
  • Planned use of fenestrated or chimney stent grafts
  • Study participants in which stent graft placement is abandoned for any reason, and/or in which the investigator decides, during the course of the stent graft placement, that the study procedure may not be appropriate
  • Planned use of embolic devices other than the product to embolize the AAA sac
  • Vascular disease and/or anatomy that preclude the safe access and positioning of a catheter to deliver the investigational product into the AAA sac
  • Ruptured, leaking, or mycotic (infected) aneurysm
  • Aneurysmal disease of the descending thoracic aorta
  • Coagulopathy or uncontrolled bleeding disorder
  • Long-term (>6 months prior to the procedure) use of direct oral anticoagulant or any vitamin K antagonist anticoagulant use
  • Serum creatinine level >2.5 mg/dL;
  • Cerebrovascular accident within 3 months prior to the procedure
  • Myocardial infarction and/or major heart surgery within 3 months prior to the procedure
  • Atrial fibrillation that is not well rate controlled
  • Unable or unwilling to comply with study follow-up requirements
  • of \<2 years post-procedure
  • Known or to platinum, iridium, or polyurethane
  • A condition that inhibits radiographic visualization during the implantation procedure
  • History of allergy to contrast medium that cannot be managed medically
  • Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the study
  • Pregnant or a lactating female. For females of , based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of for the duration of the study
  • Prisoner or member of other vulnerable population.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Intervention

    Device: IMPEDE-FX Embolization Plug

Interventions

  • DeviceIMPEDE-FX Embolization Plug

    Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft

06

What researchers measure

Primary outcomes

  1. Incidence of related major adverse events (MAEs)

    Incidence of related major adverse events (MAEs)

    Time frame: 30 days post-procedure

  2. Efficacy - Technical Success

    Technical success, defined as filling of the residual flow lumen of the AAA sac with investigational products

    Time frame: Immediately after the intervention

Secondary outcomes

  1. Incidence of related major adverse events (MAEs)

    Incidence of related major adverse events (MAEs)

    Time frame: 5 years post-procedure

  2. Incidence of related serious adverse events (SAEs)

    Incidence of related serious adverse events (SAEs)

    Time frame: 5 years post-procedure

  3. Efficacy - Type II endoleaks

    Incidence of type II endoleaks

    Time frame: 5 years post-procedure

  4. Efficacy - Type I and type III endoleaks

    Incidence of type I and type III endoleaks

    Time frame: 5 years post-procedure

  5. Efficacy - AAA sac diameter/volume

    Change in AAA sac diameter/volume

    Time frame: 5 years post-procedure

  6. Efficacy - Open repair

    Rate of conversion to open AAA repair

    Time frame: 5 years post-procedure

  7. Efficacy - Reinterventions

    Rate of other reinterventions related to the AAA sac growth and/or complications

    Time frame: 5 years post-procedure

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Apr 2022, 9 months.

Of 43 industry-sponsored interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 73. This study's 9 months is below that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 12, 2021
StartActual
Jul 13, 2021
Primary completionActual
Apr 13, 2022
CompletionEst.
Apr 30, 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04751578
Lead sponsor
Shape Memory Medical, Inc.
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Jul 13, 2021
Primary completion
Apr 13, 2022
Completion
Apr 30, 2027 (estimated)
Last update
Dec 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion